Association of Psychological Distress in Patients With Lung Cancer
Life-Score
the Association of Psychological Distress in Patients With Advanced Lung Cancer Treated With Immunotherapy or Targeted Therapy
1 other identifier
observational
500
1 country
1
Brief Summary
Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment. Psychological distress is common and affects the efficacy and prognosis of patients with lung cancer. The systematic anti-tumor therapy may effectively relieve psychological distress including anxiety, depression, and fatigue in patients with advanced lung cancer, the relief of the psychological distress can in turn improve the therapeutic effect. In summary, this study is to explore the associations of (dynamic) psychological stress with the efficacy and survival of anti-tumor therapy including immunotherapy and targeted therapy for advanced lung cancer patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2016
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedFirst Submitted
Initial submission to the registry
January 12, 2024
CompletedFirst Posted
Study publicly available on registry
January 23, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
May 22, 2025
May 1, 2025
12 years
January 12, 2024
May 20, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Objective response rate (ORR)
Collect detailed clinical information on patients with SCLC via the electronic medical records
20 years
Disease control rate (DCR)
Collect detailed clinical information on patients with SCLC via the electronic medical records
20 years
Progression-free survival (PFS)
Collect detailed clinical information on patients with SCLC via the electronic medical records
20 years
Secondary Outcomes (1)
Overall survival (OS)
20 years
Interventions
Eligibility Criteria
Participants with lung cancer are with the standard treatment and/or are enrolled in the clinical trials.
You may qualify if:
- Histologically proven diagnosis of lung cancer
- years of age or older
- Ability to understand and the willingness to sign a written informed consent document
You may not qualify if:
- Not willing to participate in this clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 12, 2024
First Posted
January 23, 2024
Study Start
January 1, 2016
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2028
Last Updated
May 22, 2025
Record last verified: 2025-05